Your browser doesn't support javascript.
loading
Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release.
Dong, Ni; Zhu, Chune; Jiang, Junhuang; Huang, Di; Li, Xing; Quan, Guilan; Liu, Yang; Tan, Wen; Pan, Xin; Wu, Chuanbin.
Afiliação
  • Dong N; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • Zhu C; Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
  • Jiang J; Shenyang Pharmaceutical University, Benxi 117004, China.
  • Huang D; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • Li X; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • Quan G; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • Liu Y; College of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China.
  • Tan W; Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
  • Pan X; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • Wu C; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Asian J Pharm Sci ; 15(3): 347-355, 2020 May.
Article em En | MEDLINE | ID: mdl-32636952
ABSTRACT
This study aimed to prepare poly (D, L-lactic-co-glycolic acid) microspheres (PLGA-Ms) by a modified solid-in-oil-in-water (S/O/W) multi-emulsion technique in order to achieve sustained release with reduced initial burst and maintain efficient drug concentration for a prolonged period of time. Composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles (Ex-NPs-PLGA-Ms) were obtained by initial fabrication of exenatide-loaded lecithin nanoparticles (Ex-NPs) via the alcohol injection method, followed by encapsulation of Ex-NPs into PLGA microspheres. Compared to Ms prepared by the conventional water-in-oil-in-water (W/O/W) technique (Ex-PLGA-Ms), Ex-NPs-PLGA-Ms showed a more uniform particle size distribution, reduced initial burst release, and sustained release for over 60 d in vitro. Cytotoxicity studies showed that Ms prepared by both techniques had superior biocompatibility without causing any detectable cytotoxicity. In pharmacokinetic studies, the effective drug concentration was maintained for over 30 d following a single subcutaneous injection of two types of Ms formulation in rats, potentially prolonging the therapeutic action of Ex. In addition, administration of Ex-NPs-PLGA-Ms resulted in a more smooth plasma concentration-time profile with a higher area under the curve (AUC) compared to that of Ex-PLGA-Ms. Overall, Ex-NPs-PLGA-Ms prepared by the novel S/O/W method could be a promising sustained drug release system with reduced initial burst release and prolonged therapeutic efficacy.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article